This review discusses medication options to manage cognitive and behavioral symptoms in neurocognitive disorders, indicating important clinical implications.
Neurocognitive disorders (NCDs) encompass various conditions that affect cognition and functioning in activities of daily living. Although many types of NCDs lack curative therapy, medications may be used to ameliorate cognitive as well as behavioral and psychological symptoms of dementia (BPSD). Medications classified as acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and antiamyloid monoclonal antibodies target cognitive symptoms. For BPSD, antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants have been studied. Selection of pharmacotherapies requires careful risk-benefit analysis for individual patients. This review discusses available evidence to guide these discussions and clinical decisions.
No takes yet. Share an insight, caveat, or question.
Olson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: